drugset / Trial / NCT06448754
Volrustomig Priming Regimens Exploratory Phase II Platform Study
RandomizedParallel-groupOpen-labelTreatment
Summary
Purpose of this study is to assess the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of volrustomig in combination with other anticancer drugs in participants with specified solid tumors.
Timeline
- Start
- 2024-08-27
- Primary completion
- 2027-07-30
- Completion
- 2027-07-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paclitaxel | Small molecule | — | Intravenous |
| Subject | Pemetrexed | Small molecule | — | Intravenous |
| Subject | Ramucirumab | Monoclonal antibody | — | Intravenous |
| Subject | Volrustomig | Monoclonal antibody | — | Intravenous |
| Background | Carboplatin | Small molecule | — | Intravenous |